Metadata record for the article: Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

SummaryThis metadata record provides details of the data supporting the claims of the related article: “Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia”.The related study aimed to generate a murine pro-B cell model of ATF7IP-JAK2 with acquired resistance to multiple type-I JAK inhibitors. Type of data: exome sequencing data; flow cytometry; computational modelling Subject of data: Homo sapiens; antibodies; eukaryotic cell lines (parental Ba/F3 cell line)Recruitment: Cryopreserved bone marrow mononuclear cell samples from Ph-like B-ALL patients were obtained from the Children’s Cancer Institute Australia (CCIA), SA Pathology/Royal Adelaide Hospital, Australasian Leukaemia & Lymphoma Group (ALLG) tissue bank, or Queensland Children’s Tumour Bank. Data accessThe exome sequencing data are openly available in the NCBI Sequence Read Archive via the following accession: https://identifiers.org/ncbi/bioproject:PRJNA741841. All additional data files underlying the Figures and Supplementary Figures of the related article are shared openly as part of this figshare data record. Files underlying Figures:ATF7IP-JAK2_BaF3_pSTAT5Timecourse_Histograms.pdfATF7IP-JAK2_RuxR_TypeIJAKInhib_CellViabilities.xlsxG993A_JAK2r_BaF3_GFP.pdfNonMutG993A_BaF3_RUX_CellViabilities.xlsxNotMutG993A_TypeIJAKInhib_pSTAT5.xlsxATF7IP-JAK2_RuxR_CHZ868_CellViabilities.xlsxNonMutG993ABaF3_pSTAT5_CHZ868.pdf Files underlying Supplementary Figures:ATF7IP-JAK2_BaF3_GFP-Layout.pdfUnprocessed_WBImages.pdfATF7IP-JAK2_RuxR_TrypanCounts.xlsxEmptyVector_BaF3_JAKInhib_CellViabilities.xlsxJAK2r_BaF3_GFP.pdfNonMut_JAK2_BaF3_HAExp.pdfCellProliferation_Luminescence.xlsxNonMutG993A_pSTAT135Phosphoflow.pdfJAK2NonMutG993A_CellProliferation_Luminescence.xlsxNonMutG993A_pAKTpERK_MFI.xlsx Corresponding author(s) for this studyProfessor Deborah White, Director: Cancer Program. Deputy Theme Leader: Precision Medicine. South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000; [e-mail] Study approval The use of samples was approved by Central Adelaide Local Health Network and the Royal Adelaide Hospital Human Research Ethics Committee. Samples were obtained with informed consent for prospective unspecified medical research, and to perform laboratory-based assays on existing specimens. All the participants were required to provide informed consent for their samples to be used in accordance with the Declaration of Helsinki.

数据集概述：本元数据记录详细阐述了支撑相关论文《获得性JAK2突变在急性淋巴细胞白血病细胞模型中赋予JAK抑制剂耐药性》研究结论的数据集详情。本相关研究旨在构建携带ATF7IP-JAK2融合基因、可对多种I型JAK抑制剂（Type-I JAK inhibitors）产生获得性耐药的小鼠前B细胞模型。
数据类型：外显子组测序（exome sequencing）数据、流式细胞术（flow cytometry）数据、计算建模（computational modelling）数据
数据主题：智人（Homo sapiens）、抗体、真核细胞系（亲本Ba/F3细胞系（Ba/F3 cell line））
样本招募：从澳大利亚儿童癌症研究所（CCIA）、南澳病理/皇家阿德莱德医院、澳大利亚白血病与淋巴瘤小组（ALLG）组织库，以及昆士兰儿童肿瘤库获取Ph样B细胞急性淋巴细胞白血病（Ph-like B-ALL）患者的冻存骨髓单个核细胞样本。

数据获取：外显子组测序数据可通过以下登录号在NCBI序列读取档案库（NCBI Sequence Read Archive）公开获取：https://identifiers.org/ncbi/bioproject:PRJNA741841。相关论文附图及补充附图所依托的全部额外数据文件，均作为本figshare数据记录的一部分公开共享。
附图所依托文件：
ATF7IP-JAK2_BaF3_pSTAT5Timecourse_Histograms.pdf
ATF7IP-JAK2_RuxR_TypeIJAKInhib_CellViabilities.xlsx
G993A_JAK2r_BaF3_GFP.pdf
NonMutG993A_BaF3_RUX_CellViabilities.xlsx
NotMutG993A_TypeIJAKInhib_pSTAT5.xlsx
ATF7IP-JAK2_RuxR_CHZ868_CellViabilities.xlsx
NonMutG993ABaF3_pSTAT5_CHZ868.pdf

补充附图所依托文件：
ATF7IP-JAK2_BaF3_GFP-Layout.pdf
Unprocessed_WBImages.pdf
ATF7IP-JAK2_RuxR_TrypanCounts.xlsx
EmptyVector_BaF3_JAKInhib_CellViabilities.xlsx
JAK2r_BaF3_GFP.pdf
NonMut_JAK2_BaF3_HAExp.pdf
CellProliferation_Luminescence.xlsx
NonMutG993A_pSTAT135Phosphoflow.pdf
JAK2NonMutG993A_CellProliferation_Luminescence.xlsx
NonMutG993A_pAKTpERK_MFI.xlsx

本研究通讯作者：黛博拉·怀特教授，癌症项目主任、精准医学主题组副组长，南澳健康与医学研究所，阿德莱德北台地，南澳大利亚5000；电子邮箱：[e-mail]

研究伦理审批：样本使用已获得中央阿德莱德本地卫生网络及皇家阿德莱德医院人类研究伦理委员会批准。样本获取已获得受试者知情同意，可用于前瞻性非特定医学研究及对现有样本开展实验室检测。所有参与者均需按照《赫尔辛基宣言（Declaration of Helsinki）》的要求，为其样本的使用提供知情同意。